Pharmacological, Biochemical and Therapeutic Potential of Milk Thistle (Silymarin): A Review

Silymarin, a flavonolignan from the seeds of 'milk thistle' ( Silybum marianum (L.) Gaertn.)), has been widely used from ancient times because of its excellent hepato-protective action. It is a mixture of mainly three flavonolignans, which are, silybin, silidianin, and silychristin, with silybin being the most active. Silymarin has been used medicinally to treat liver disorders, including acute and chronic viral hepatitis, toxin/drug-induced hepatitis, and cirrhosis and alcoholic liver diseases. It has also been reported to be effective in certain cancers. Its mechanism of action includes inhibition of hepatotoxin binding to receptor sites on the hepatocyte membrane; reduction of glutathione oxidation to enhance its level in the liver and intestine; antioxidant activity; and stimulation of ribosomal RNA polymerase and subsequent protein synthesis, leading to enhanced hepatocyte regeneration. It is orally absorbed but has very poor bioavailability due to its poor water solubility. This review focuses on the various pharmacological activities of silymarin.

[1]  Didunyemi Mo,et al.  Morinda lucida Attenuates Acetaminophen-Induced Oxidative Damage and Hepatotoxicity in Rats , 2019 .

[2]  Liang Liu,et al.  Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2 , 2018, Front. Pharmacol..

[3]  Liang Liu,et al.  Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies , 2017, Pharmacological research.

[4]  M. Bijak Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)—Chemistry, Bioavailability, and Metabolism , 2017, Molecules.

[5]  Peter F Surai Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives , 2015, Antioxidants.

[6]  H. Ichijo,et al.  Mitochondrial proteolysis: its emerging roles in stress responses. , 2015, Biochimica et biophysica acta.

[7]  M. Tuorkey,et al.  Cytoprotective effect of silymarin against diabetes-induced cardiomyocyte apoptosis in diabetic rats. , 2015, Biomedical and environmental sciences : BES.

[8]  Y. Liu,et al.  Silymarin induces cell cycle arrest and apoptosis in ovarian cancer cells. , 2014, European journal of pharmacology.

[9]  N. Zeghal,et al.  Protective role of silymarin against manganese‐induced nephrotoxicity and oxidative stress in rat , 2014, Environmental toxicology.

[10]  S. Cho,et al.  Protective effect of silymarin against cisplatin-induced ototoxicity. , 2014, International journal of pediatric otorhinolaryngology.

[11]  Debapriya Garabadu,et al.  Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats , 2014, Pharmacology Biochemistry and Behavior.

[12]  Bin Xu,et al.  Silybum marianum oil attenuates oxidative stress and ameliorates mitochondrial dysfunction in mice treated with D-galactose , 2014, Pharmacognosy magazine.

[13]  V. Křen,et al.  Biotransformation of silybin and its congeners. , 2013, Current drug metabolism.

[14]  J. Markowitz,et al.  An Assessment of Pharmacokinetics and Antioxidant Activity of Free Silymarin Flavonolignans in Healthy Volunteers: A Dose Escalation Study , 2013, Drug Metabolism and Disposition.

[15]  P. Portincasa,et al.  A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. , 2013, World journal of gastroenterology.

[16]  M. Aschner,et al.  Manganese Neurotoxicity: a Focus on Glutamate Transporters , 2013, Annals of Occupational and Environmental Medicine.

[17]  G. Subramanya,et al.  Antioxidant and Anti-Hepatitis C Viral Activities of Commercial Milk Thistle Food Supplements , 2013, Antioxidants.

[18]  S. Witkin,et al.  Silibinin attenuates oxidative metabolism and cytokine production by monocytes from preeclamptic women , 2013, Free radical research.

[19]  N. Zeghal,et al.  Therapeutic efficacy of silymarin from milk thistle in reducing manganese-induced hepatic damage and apoptosis in rats , 2013, Human & experimental toxicology.

[20]  L. Calani,et al.  Absorption and metabolism of milk thistle flavanolignans in humans. , 2012, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[21]  K. Reddy,et al.  Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. , 2012, Journal of the American Medical Association (JAMA).

[22]  A. C. Santos,et al.  Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update , 2012, Archives of Toxicology.

[23]  N. Nalini,et al.  Colon cancer chemopreventive efficacy of silibinin through perturbation of xenobiotic metabolizing enzymes in experimental rats. , 2012, European journal of pharmacology.

[24]  R. Saller,et al.  The Use of Silymarin in the Treatment of Liver Diseases , 2012, Drugs.

[25]  N. Zeghal,et al.  Improvement of Cerebellum Redox States and Cholinergic Functions Contribute to the Beneficial Effects of Silymarin Against Manganese-Induced Neurotoxicity , 2011, Neurochemical Research.

[26]  P. Chanvorachote,et al.  Silymarin selectively protects human renal cells from cisplatin-induced cell death , 2011, Pharmaceutical biology.

[27]  Mushir M. Ali,et al.  Reassessing bioavailability of silymarin. , 2011, Alternative medicine review : a journal of clinical therapeutic.

[28]  V. Křen,et al.  Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  C. Loguercio,et al.  Silybin and the liver: from basic research to clinical practice. , 2011, World journal of gastroenterology.

[30]  Jianhui Liu,et al.  Silibinin: A novel inhibitor of Aβ aggregation , 2011, Neurochemistry International.

[31]  D. Abo-Elmatty,et al.  Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. , 2011, European journal of pharmacology.

[32]  J. Ježek,et al.  Dehydrosilybin attenuates the production of ROS in rat cardiomyocyte mitochondria with an uncoupler-like mechanism , 2010, Journal of bioenergetics and biomembranes.

[33]  E. Ernst The Review of Natural Products , 2010 .

[34]  N. Zeghal,et al.  Silymarin, a natural antioxidant, protects cerebral cortex against manganese-induced neurotoxicity in adult rats , 2010, BioMetals.

[35]  M. Doležal,et al.  Substituted Pyrazinecarboxamides as Abiotic Elicitors of Flavolignan Production in Silybum marianum (L.) Gaertn Cultures in Vitro , 2010, Molecules.

[36]  Mingzhang Lin,et al.  Free radical scavenging reactions and antioxidant activities of silybin: Mechanistic aspects and pulse radiolytic studies , 2009, Free radical research.

[37]  X. Leverve,et al.  Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. , 2008, Life sciences.

[38]  P. Haddad,et al.  Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. , 2008, Journal of ethnopharmacology.

[39]  S. J. Schrieber,et al.  Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract , 2008, Drug Metabolism and Disposition.

[40]  Lie-Chwen Lin,et al.  Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. , 2007, Journal of pharmaceutical and biomedical analysis.

[41]  K. Lemr,et al.  Silybin Is Metabolized by Cytochrome P450 2C8 in Vitro , 2007, Drug Metabolism and Disposition.

[42]  A. Gescher,et al.  Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (Silybum marianum), in human plasma by high-performance liquid chromatography and identification of possible metabolites. , 2007, Journal of Agricultural and Food Chemistry.

[43]  V. Křen,et al.  Silybin and silymarin--new and emerging applications in medicine. , 2007, Current medicinal chemistry.

[44]  H. Hafez,et al.  Silymarin modulates Cisplatin-induced oxidative stress and hepatotoxicity in rats. , 2006, Journal of biochemistry and molecular biology.

[45]  C. Girish,et al.  Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. , 2006, The Indian journal of medical research.

[46]  Li‐jun Wu,et al.  Silibinin protects rat cardiac myocyte from isoproterenol-induced DNA damage independent on regulation of cell cycle. , 2006, Biological & pharmaceutical bulletin.

[47]  A. Dennison,et al.  Pilot Study of Oral Silibinin, a Putative Chemopreventive Agent, in Colorectal Cancer Patients: Silibinin Levels in Plasma, Colorectum, and Liver and Their Pharmacodynamic Consequences , 2006, Clinical Cancer Research.

[48]  S. Antus,et al.  Structure prerequisite for antioxidant activity of silybin in different biochemical systems in vitro. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[49]  V. Křen,et al.  Silybin and silymarin--new effects and applications. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[50]  L. Pérez,et al.  Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide. , 2005, Life sciences.

[51]  R. Agarwal,et al.  Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. , 2005, Cancer research.

[52]  Y. H. Han,et al.  Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. , 2004, Journal of pharmaceutical and biomedical analysis.

[53]  Tianyi Zhang,et al.  Application of liquid chromatography-electrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[54]  P. Oliveira,et al.  Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[55]  S. Thakur SILYMARIN-A HEPATOPROTECTIVE AGENT , 2002 .

[56]  S. Bhattacharya,et al.  Effect of Withania somnifera glycowithanolides on iron‐induced hepatotoxicity in rats , 2000, Phytotherapy research : PTR.

[57]  R. Agarwal,et al.  Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. , 1999, Carcinogenesis.

[58]  K. Soliman,et al.  Food Constituents Attenuate Monoamine Oxidase Activity and Peroxide Levels in C6 Astrocyte Cells , 1998, Planta medica.

[59]  H. de Groot,et al.  Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin , 1996, Hepatology.

[60]  H. de Groot,et al.  Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. , 1996, Life sciences.

[61]  B. Lokesh,et al.  Effect of curcumin and eugenol on iron-induced hepatic toxicity in rats. , 1996, Toxicology.

[62]  J. Tao,et al.  Hepatoprotective properties of Silybum marianum herbal preparation on ethanol-induced liver damage , 1996 .

[63]  G. Krumbiegel,et al.  Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection. , 1995, Journal of chromatography. B, Biomedical applications.

[64]  P. Morazzoni,et al.  Silybum marianum (Carduus marianus) , 1995 .

[65]  A. Srivastava,et al.  Effect of picroliv and silymarin on liver regeneration in rats , 1994 .

[66]  H. Mascher,et al.  Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[67]  V. Fintelmann Modern phytotherapy and its uses in gastrointestinal conditions. , 1991, Planta medica.

[68]  G. Labbe,et al.  Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. , 1990, Biochemical pharmacology.

[69]  D. Lorenz,et al.  Pharmacokinetic studies with silymarin in human serum and bile. , 1984, Methods and findings in experimental and clinical pharmacology.

[70]  P. Flory,et al.  [Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose]. , 1980, Planta medica.

[71]  J. Meldolesi,et al.  Liver protection by silymarin: in vitro effect on dissociated rat hepatocytes. , 1976, Arzneimittel-Forschung.

[72]  A. Desplaces,et al.  The effects of silymarin on experimental phalloidine poisoning. , 1975, Arzneimittel-Forschung.

[73]  C. Panne,et al.  [Searching for a new therapeutic principle. Experience with hepatic therapeutic agent Legalon]. , 1969, Die Medizinische Welt.